GSTs have the ability to detoxify cytostatic drugs (151). Therefore, chemotherapy-resistant ovarian cancer cells might develop resistance by upregulating the miR-133b-target gene GST-π. The gene discussed is HPGDS; the disease is ovarian carcinoma.